Trial Condition(s):

Venous Thromboembolism (VTE)

Study to gather information how often venous thromboembolism occurs in prostate cancer patients in Sweden and how this condition is treated with blood thinners (PRACTISE)

Bayer Identifier:

20653

ClinicalTrials.gov Identifier:

NCT03965741

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary embolism) and is a leading cause of condition of being diseased and death among cancer patients. The goal of the study is to gather information how often venous thromboembolism (VTE) occurs in prostate cancer patients in Sweden and how this condition is treated with blood thinners.

Inclusion Criteria
-Initially all patients newly diagnosed with PCa between 2007-2016 with at least one year before the end of follow up date (31 December 2017) will be included. From this population, a sub-population of PCa patients with a first cancer-related VTE event will be selected.
Exclusion Criteria
-None

Trial Summary

Enrollment Goal
97765
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many Locations

Many Locations, Sweden

Status
Completed
 

Trial Design